Search Page

1

Cite

Share

Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial.

Bergougnan L, Andersen G, Plum-Mörschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA. Bergougnan L, et al. Among authors: hurbin f. Br J Clin Pharmacol. 2021 May;87(5):2303-2320. doi: 10.1111/bcp.14632. Epub 2020 Nov 26. Br J Clin Pharmacol. 2021. PMID: 33125753 Free PMC article. Clinical Trial.

Cite

Share

2

Cite

Share

First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.

Bergougnan L, Armani S, Golor G, Tardat A, Vitse O, Hurbin F, Scemama M, Poitiers F, Radzik D, Gaudin C, Hovsepian L, Muslin AJ, Kirkesseli S, Deutsch P, Parkar AA. Bergougnan L, et al. Among authors: hurbin f. Br J Clin Pharmacol. 2021 Feb;87(2):598-611. doi: 10.1111/bcp.14422. Epub 2020 Jul 8. Br J Clin Pharmacol. 2021. PMID: 32520410 Free article. Clinical Trial.

Cite

Share

3

Cite

Share

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I.

Martinez JM, Brunet A, Hurbin F, DiCioccio AT, Rauch C, Fabre D. Martinez JM, et al. Among authors: hurbin f. Clin Pharmacokinet. 2019 Jan;58(1):101-113. doi: 10.1007/s40262-018-0669-y. Clin Pharmacokinet. 2019. PMID: 29725996 Free PMC article. Clinical Trial.

Cite

Share

4

Cite

Share

Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.

Boulenc X, Djebli N, Shi J, Perrin L, Brian W, Van Horn R, Hurbin F. Boulenc X, et al. Among authors: hurbin f. Drug Metab Dispos. 2012 Jan;40(1):187-97. doi: 10.1124/dmd.111.040394. Epub 2011 Oct 17. Drug Metab Dispos. 2012. PMID: 22004687 Clinical Trial.

Cite

Share

5

Cite

Share

Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.

Djebli N, Martinez JM, Lohan L, Khier S, Brunet A, Hurbin F, Fabre D. Djebli N, et al. Among authors: hurbin f. Clin Pharmacokinet. 2017 Oct;56(10):1155-1171. doi: 10.1007/s40262-016-0505-1. Clin Pharmacokinet. 2017. PMID: 28063030 Free PMC article.

Cite

Share

6

Cite

Share

Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.

Hurbin F, Boulenc X, Daskalakis N, Farenc C, Taylor T, Bonneau D, Lacreta F, Cheng S, Sultan E. Hurbin F, et al. J Clin Pharmacol. 2012 Oct;52(10):1506-15. doi: 10.1177/0091270011419852. Epub 2011 Nov 29. J Clin Pharmacol. 2012. PMID: 22128201 Clinical Trial.

Cite

Share

7

Cite

Share

An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma.

Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N, Savi P, Bremond N, Rouchon MC, Hurbin F, Sultan E. Tuffal G, et al. Among authors: hurbin f. Thromb Haemost. 2011 Apr;105(4):696-705. doi: 10.1160/TH10-09-0582. Epub 2011 Feb 8. Thromb Haemost. 2011. PMID: 21301779

Cite

Share

8

Cite

Share

Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.

Djebli N, Fabre D, Boulenc X, Fabre G, Sultan E, Hurbin F. Djebli N, et al. Among authors: hurbin f. Drug Metab Dispos. 2015 Apr;43(4):510-22. doi: 10.1124/dmd.114.062596. Epub 2015 Jan 21. Drug Metab Dispos. 2015. PMID: 25609219 Clinical Trial.

Cite

Share

9

Cite

Share

Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.

Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M. Angiolillo DJ, et al. Among authors: hurbin f. Clin Pharmacol Ther. 2011 Jan;89(1):65-74. doi: 10.1038/clpt.2010.219. Epub 2010 Sep 15. Clin Pharmacol Ther. 2011. PMID: 20844485 Clinical Trial.

Cite

Share

10

Cite

Share

Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.

Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M. Simon T, et al. Among authors: hurbin f. Clin Pharmacol Ther. 2011 Aug;90(2):287-95. doi: 10.1038/clpt.2011.127. Epub 2011 Jun 29. Clin Pharmacol Ther. 2011. PMID: 21716274 Clinical Trial.

Cite

Share